🦠 Group A Streptococcus Vaccine Tracker Dashboard

Updated July 2026. This page tracks the broader Streptococcus vaccine landscape. See also the dedicated Group A Strep tracker for VAX-A1 (Vaxcyte, Phase 1 first-in-human dosing June 2, 2026) and StreptAnova/J8 peptide vaccines. For Group B Streptococcus (GBS) — a leading cause of neonatal sepsis and meningitis — Pfizer's hexavalent GBS conjugate vaccine PF-06760805 completed a Phase 2 trial in pregnant women; MinervaX's GBS6 protein-based vaccine advancing through Phase 2. Combined GAS+GBS approaches (leveraging cross-reactive ScpA/ScpB immunity — see Vaxcyte VAX-A1 preclinical) remain a promising unified pathway. No approved GBS vaccine yet exists globally.

Comprehensive tracking of Group A Streptococcus (GAS) vaccine development to prevent strep throat, rheumatic fever, rheumatic heart disease, and invasive streptococcal infections. GAS causes 500,000+ deaths annually, primarily from rheumatic heart disease (319,000 deaths) and invasive infections. No licensed vaccine exists despite century of research. Multiple M-protein based vaccines in Phase 1-3 trials targeting streptococcal pharyngitis, scarlet fever, and autoimmune complications. This tracker monitors 30-valent M-protein vaccines, conserved epitope approaches, and next-generation platforms for GAS prevention.

⚠️ MAJOR GLOBAL HEALTH BURDEN:

Group A Streptococcus causes 500,000+ deaths annually: 319,000 from rheumatic heart disease, 163,000 from invasive GAS, plus complications including acute rheumatic fever (33M cases), post-streptococcal glomerulonephritis, and pediatric autoimmune neuropsychiatric disorders (PANDAS). 600M cases of strep throat yearly. Disproportionately affects low-income countries and Indigenous populations.

Group A Strep Vaccines by Development Phase